CG
NTLA icon

Cutler Group’s Intellia Therapeutics NTLA Stock Holding History

Cutler Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-400
Closed -$1K – 5315
2022
Q2 		$1K Sell
400
-200
-33% -$10.2K ﹤0.01% 4666
2022
Q1 		$4K Buy
+600
New +$50.8K ﹤0.01% 4301
2021
Q4 		– Sell
-1,200
Closed -$9K – 5844
2021
Q3 		$9K Sell
1,200
-8,500
-88% -$1.29M ﹤0.01% 4028
2021
Q2 		$271K Buy
+9,700
New +$755K 0.01% 1129
2018
Q1 		– Sell
-5,700
Closed -$11K – 4983
2017
Q4 		$11K Buy
5,700
+700
+14% +$16.2K ﹤0.01% 3054
2017
Q3 		$39K Buy
5,000
+4,600
+1,150% +$86.7K ﹤0.01% 2475
2017
Q2 		$1K Buy
+400
New +$5.59K ﹤0.01% 5961

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cutler Group's NTLA Position: Q1 2024 in Review

Cutler Group sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 200 shares — an estimated $6K sold.

Cutler Group first reported a position in NTLA in Q2 2017 and held it in 16 quarters. The position peaked at $1.49M in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Cutler Group reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 200 Intellia Therapeutics shares in Q1 2024, an estimated $6K.
  • Cutler Group first reported a position in Intellia Therapeutics in Q2 2017 and held it in 16 quarters.
  • Cutler Group's Intellia Therapeutics position peaked at $1.49M in Q2 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.